Bolt Biotherapeutics, Inc. (BOLT)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-12

Key Insights

Company released Q1 2026 financial results and business update on May 12, 2026, indicating continued operational reporting and transparency with investors.
CEO William P. Quinn serves as both President and Chief Financial Officer, suggesting a lean management structure typical of emerging growth companies that may limit segregation of duties.
The filing is furnished rather than filed, meaning the press release and financial information are not subject to liability under Securities Act sections 11 and 12(a)(2), reducing disclosure obligations for this earnings announcement.
As a Nasdaq Capital Market listed emerging growth company, Bolt has elected not to use extended transition periods for new accounting standards, indicating a commitment to full compliance with current standards.

Quarterly Report Filed: 2026-05-12

Key Insights

Filing contains extensive fair value measurements and financial instruments data across multiple levels (Level 1, 2, and 3), indicating complex portfolio management and potential valuation challenges that warrant investor scrutiny.
October 2025 restructuring plan is referenced multiple times throughout the filing, suggesting significant organizational changes that likely impacted Q1 2026 operations and may affect future cash burn and profitability.
Genmab Agreement and Toray Development Agreement are both active during the Q1 2026 period, indicating ongoing partnerships that could represent revenue opportunities or funding mechanisms for the biotech company.
Multiple lease-related entries (Chesapeake Master Lease dating back to 2020) suggest ongoing real estate commitments that represent fixed obligations affecting cash flow analysis.

Current Report Filed: 2026-03-12

Key Insights

Bolt Biotherapeutics reported its Q4 2025 and full-year 2025 financial results, indicating the company's ongoing progress and development of its pipeline.
The company did not provide any guidance or updates on key clinical programs, which may raise some uncertainty among investors about the near-term outlook.
As an emerging growth company, Bolt Biotherapeutics has the option to take advantage of extended transition periods for complying with new or revised financial accounting standards, which could impact financial reporting and transparency.

Annual Report Filed: 2026-03-12

Key Insights

The company reported a significant increase in research and development expenses, indicating a focus on expanding its pipeline of biotherapeutic products.
Bolt Biotherapeutics entered into several key agreements, such as the Genmab and Toray Development Agreements, which could provide additional revenue streams and collaboration opportunities.
The company has a strong cash position with $XXX million in cash and marketable securities, which should provide sufficient funding for ongoing operations and future growth initiatives.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Sarah Nemec, acquired 125 shares of common stock of Bolt Biotherapeutics, Inc. through an employee stock purchase plan transaction on December 5, 2025.
Nemec also received an 8,000 share stock option grant on January 28, 2026, which vests over 36 months of continuous service.
These transactions suggest Nemec, a senior finance executive, has confidence in the company and is increasing her ownership stake.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Grant Yonehiro, was granted 10,000 stock options as the Chief Operating Officer of Bolt Biotherapeutics, Inc. (BOLT), with a strike price of $6.71 and a 10-year expiration date.
The stock options will vest over a 3-year period, with 1/36th of the shares vesting each month, indicating a long-term commitment from the executive to the company.
This filing indicates insider ownership and alignment between management and shareholders, which can be a positive signal for investors.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, William P. Quinn, purchased 125 shares of common stock in the company, indicating potential confidence in the company's outlook.
Quinn, who is the President, CEO and CFO, was granted 20,000 stock options with a 10-year expiration, aligning his incentives with long-term shareholder value creation.
The insider trading activity suggests that management is optimistic about the company's future prospects and is willing to invest in the stock.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.